Cancer Lipid Metabolism
Cancer Molecular Therapies
Cancer Metabolism: Long History, Recent Breakthrough
Fatty Acid Synthase, A Promising Cancer Drug Target
Cancer Lipid Metabolism: Recent Breakthrough of FASN Inhibitors
• Investigator sponsored Phase 2 trial of TVB-2640 with Bevacizumab in Patients with First Relapse of High-Grade Astrocytoma
• 25 patients enrolled, both grade III and IV astrocytoma
• All patients received ASC40 (TVB-2640) (100mg/m2 PO QD) plus bevacizumab (10mg/kg IV D1,15) until treatment-related toxicity or progressive disease
• The overall response rate (ORR) for ASC40 (TVB-2640) plus bevacizumab of 65%
• Complete response (CR) of 20%
• Partial response (PR) of 45%
• Progression-free survival at six months (PFS6) for ASC40 (TVB-2640) plus bevacizumab was 47%
• Representing a statistically significant improvement in PFS6 over historical bevacizumab monotherapy (BELOB 16%, P=0.01)
• ASC40 (TVB-2640) in combination with bevacizumab was safe and well tolerated in such patient population
• Presented at European Society for Medical Oncology 2020
Oral Checkpoint Inhibitors
PD-L1 Small Molecule Inhibitors: Challenges and Opportunities
ASC63: Induce PD-L1 Dimerization and Sustained Internalization
Publications
Title | Venue | Type | Date |
Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma | Clinical Cancer Research | Paper | 04/2023 |
In vivo Efficacy Evaluation of ASC61, an Oral PD-L1 Inhibitor, in Two Tumor Mouse Models | The 2022 Annual Meeting of the American Association for Cancer Research (AACR) | Poster | 3/2022 |
Efficacy of ASC60, an Oral Fatty Acid Synthase Inhibitor,in Two Tumor Mouse Models | The 2022 Annual Meeting of the American Association for Cancer Research (AACR) | Poster | 3/2022 |
First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640 | The 2017 American Association for Cancer Research (AACR) Annual Meeting | Poster | 04/2017 |